Embolisation of metastatic lung lesions using radiopharmaceutical Yttrium -90 in patients with various malignancies to decrease metastatic disease burde
Phase 2
- Conditions
- Health Condition 1: C800- Disseminated malignant neoplasm, unspecifiedHealth Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
- Registration Number
- CTRI/2024/06/068822
- Lead Sponsor
- Bela Jain senior resident
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
measureable metastatic lung lesions (Biopsy proven or positive on FDG PET CT), ECOG less than or equal to 2, Karnofsky score more than 60, Hemoglobin more than 9 g/dl, WBC more than 1500/microlitre, platelets more than 50000/microlitre, PT less than 1.3 and INR less than 1.5, FEV1more than 60%, serum creatinine less than 1.3
Exclusion Criteria
previous history of interstitial lung disease, COPD, active lung infection, pulmonary hypertension, pulmonary AV malformation, Symptomatic heart failure, LBBB, Predictive dose to lung parenchyma exceeding 30 Grey in dose planning, allergy to contrast/plastic, renal failure, coagulative disorder, survival expectancy of less than 3 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method